Central nervous system effects of the second-generation antihistamines marketed in Japan--review of inter-drug differences using the proportional impairment ratio (PIR)- - Wikidata - awgldk - TriplyDB

Central nervous system effects of the second-generation antihistamines marketed in Japan--review of inter-drug differences using the proportional impairment ratio (PIR)-

Central nervous system effects of the second-generation antihistamines marketed in Japan--review of inter-drug differences using the proportional impairment ratio (PIR)-

http://www.wikidata.org/entity/Q28542698

about

On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol.A simulated car-driving study on the effects of acute administration of levocetirizine, fexofenadine, and diphenhydramine in healthy Japanese volunteers.

P2860

Q37184487-B39C56E2-4B55-494D-85BC-233DC273F1E5 Q47450319-1F16E910-25D4-4FBE-AA79-7D13E223F465

P2860

Central nervous system effects of the second-generation antihistamines marketed in Japan--review of inter-drug differences using the proportional impairment ratio (PIR)-

http://www.wikidata.org/entity/Q28542698

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Central nervous system effects ...... tional impairment ratio (PIR)-

@ast

Central nervous system effects ...... tional impairment ratio (PIR)-

@en

Central nervous system effects ...... tional impairment ratio (PIR)-

@nl

type

label

Central nervous system effects ...... tional impairment ratio (PIR)-

@ast

Central nervous system effects ...... tional impairment ratio (PIR)-

@en

Central nervous system effects ...... tional impairment ratio (PIR)-

@nl

prefLabel

Central nervous system effects ...... tional impairment ratio (PIR)-

@ast

Central nervous system effects ...... tional impairment ratio (PIR)-

@en

Central nervous system effects ...... tional impairment ratio (PIR)-

@nl

P1433

Q28542698-365594CD-9704-4F5C-BF6B-0E41526A67B3

P1476

Q28542698-63CCAD8B-8774-4D59-8F15-9F1F95AA914E

P2093

Q28542698-47F91289-659B-46B8-BD71-43EFB49F7114

Q28542698-48E2ECE9-C556-40BE-8877-1F118C1EF4A2

Q28542698-4E69B4E5-9E39-49BA-9A44-0A88B1668361

Q28542698-58C20B62-8C2A-4C99-84F8-3C7A7C687315

Q28542698-788EA141-FBA7-4257-A155-74ED8761451D

Q28542698-BF44CC3A-442A-48EF-9BFC-A0DACF9F55F6

Q28542698-FF2CCCB9-F2CF-4DEC-B0D5-725EBB62E602

P275

Q28542698-3EFA2777-8E6F-4CD8-B33E-58F2C9A2227E

P2860

Q28542698-03545B5B-23A5-4994-AA0C-9DB14201195F

Q28542698-096271EB-1A7B-4A88-8632-493AE269E06A

Q28542698-0D7D0CBE-57D7-41BF-9E2D-A772CA8DD9A5

Q28542698-132EB4EA-F66C-49FA-9FBD-4A6B03A644E8

Q28542698-16467366-9543-40CB-9827-C93E6A5A50CF

Q28542698-1A885BD0-7AFF-4CD9-910B-6408B63B1D86

Q28542698-1BDB94A6-772D-4151-9C88-F5F357BD74E4

Q28542698-26895C30-DBEE-4A0F-95D5-5D0CD14576EC

Q28542698-2D1DFA64-C1D8-46AF-BD71-3A95860027AE

Q28542698-3A279552-F9BF-4668-A216-A7BF9DDFFF68

P304

Q28542698-2D4EE8D1-AFFD-4923-92B8-8D4D775602B7

P31

Q28542698-B5D853D6-3B4C-43FE-942B-1AAA1C69E4DF

Q28542698-CEBD874F-8ACF-4751-90A8-B37BFA69D0CA

P3181

Q28542698-BF1765C8-D3D8-43C2-8931-2209115BF30D

P356

Q28542698-FBF751D6-5E43-4642-8E42-162E766A640B

P407

Q28542698-EE49D74A-EA6B-4879-ADC3-FAB74E16C0F9

P433

Q28542698-4A57C514-832D-4F53-93CB-5DB0E4EFD8B0

P478

Q28542698-5A019BAA-C9BA-44C8-8391-FB9B3465EC50

P577

Q28542698-58579394-A7A3-4CED-8129-3AFC93274709

P5875

Q28542698-6E4FB1C6-00AC-4CCF-AFF3-2EBF251E3523

P698

Q28542698-D27AEA1E-038F-40FE-8CF1-FA8BBB9E8DD2

P921

Q28542698-1425E1BB-3C4D-4C43-A3CF-405EB698A812

Q28542698-5E6F7B63-BC79-4AA7-8B05-2EC16E3693AB

Q28542698-7DAFA2AB-F11B-4763-AC1F-2A90253F8B52

Q28542698-97B3748F-7387-4AB3-82E6-BA6EF402D108

P932

Q28542698-87CAF4E1-0D00-4234-84B9-9C698172CF1C

P3181

P356

JOURNAL.PONE.0114336

P1433

P1476

Central nervous system effects ...... tional impairment ratio (PIR)-

@en

P2093

Aya Murakami

http://www.w3.org/2001/XMLSchema#string

Ian Hindmarch

http://www.w3.org/2001/XMLSchema#string

Kyoko Inuzuka

http://www.w3.org/2001/XMLSchema#string

Norimasa Kikuchi

http://www.w3.org/2001/XMLSchema#string

Seiji Kawana

http://www.w3.org/2001/XMLSchema#string

Takeshi Kono

http://www.w3.org/2001/XMLSchema#string

Tatsuya Isomura

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

A dose-ranging study of the effects of mequitazine on actual driving, memory and psychomotor performance as compared to dexchlorpheniramine, cetirizine and placebo

Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance

Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.

Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography.

The effects of single and repeated administration of ebastine on cognition and psychomotor performance in comparison to triprolidine and placebo in healthy volunteers.

Placebo controlled comparison of acute effects of ebastine and clemastine on performance and EEG.

Antihistamines, drowsiness, and psychomotor impairment: central nervous system effect of cetirizine.

Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios.

Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations.

Effects of single therapeutic doses of promethazine, fexofenadine and olopatadine on psychomotor function and histamine-induced wheal- and flare-responses: a randomized double-blind, placebo-controlled study in healthy volunteers

P304

e114336

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4137445

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0114336

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269717436

http://www.w3.org/2001/XMLSchema#string

P698

25501360

http://www.w3.org/2001/XMLSchema#string

P921

psychomotor disease

histamine antagonist

mechanism of action

P932

4264760

http://www.w3.org/2001/XMLSchema#string